The European Federation of Pharmaceutical Industries and Associations (EFPIA) has published the white paper “Advancing precision oncology treatment and testing across Europe: An evidence-based roadmap for healthcare system stakeholders to improve cancer care”.
The document presents a practical implementation toolkit for Member States, drawing on fifteen case studies and promising practices from Europe and beyond. It also explores the role of EU-level policy levers in helping Member States to scale up best practices and reduce disparities. The paper identifies recurring system ‘archetypes’ that hinder progress and sets out targeted, sequenced policy actions across three priority areas:
- Raising awareness among patients, healthcare professionals, and payers of the value and practical implications of precision oncology.
- Strengthening infrastructure and workforce capacity, including molecular testing platforms, multidisciplinary tumour boards, and training pathways.
- Aligning funding and reimbursement systems so that diagnostics and targeted therapies advance together in a timely manner.